Looking ahead to the final months of 2025 and into 2026, it is hoped that the upward momentum in overall deal value and incidence of larger deals continues. However, it would not be surprising if overall deal volumes at the end of 2025 remain consistent with recent years (rather than activity levels taking a significant upward turn). Strategics are expected to continue to be the key driver of activity; but, if the return of some more sizeable PE led deals signals renewed confidence for investment in the sector, then 2026 could see a shift change in deal making momentum.
Read the full article: Biopharma M&A Activity – Strategics Continue to Lead the Way //
Source: https://www.hsfkramer.com/notes/lifesciences/2025-posts/biopharma-ma-activity-as-we-enter-the-latter-months-of-2025-strategics-continue-to-lead-the-way